Evidence map›Paper›PMID 33836243›Full record

ArticleNeuroscience2021

The K

Bryan S Barker, Jay Spampanato, Hilary S McCarren, Kyle Berger, Cecelia E Jackson, David T Yeung, F Edward Dudek, John H McDonough

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. KArchiv der Pharmazie · 2026
    Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Bryan S BarkerUnited States Army Medical Research Institute of Chemical Defense, Medical Toxicology Research Division, Neuroscience Department, 2900 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010, USA.
Jay SpampanatoDepartment of Neurosurgery, University of Utah School of Medicine, Salt Lake City, UT 84108, USA. Electronic address: jay.spampanato@utah.edu.
Hilary S McCarrenUnited States Army Medical Research Institute of Chemical Defense, Medical Toxicology Research Division, Neuroscience Department, 2900 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010, USA.
Kyle BergerUnited States Army Medical Research Institute of Chemical Defense, Medical Toxicology Research Division, Neuroscience Department, 2900 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010, USA.
Cecelia E JacksonUnited States Army Medical Research Institute of Chemical Defense, Medical Toxicology Research Division, Neuroscience Department, 2900 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010, USA.
David T YeungNational Institutes of Health/National Institute of Allergy and Infectious Disease, Bethesda, MD 20892, USA.
F Edward DudekDepartment of Neurosurgery, University of Utah School of Medicine, Salt Lake City, UT 84108, USA.
John H McDonoughUnited States Army Medical Research Institute of Chemical Defense, Medical Toxicology Research Division, Neuroscience Department, 2900 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010, USA.
United States Army · USUniversity of Utah · USNational Institutes of Health · US

Funding

Acquisition of A MALDI-TOF Mass SpectrometerS10OD018013 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEARY, JULIE ANN · 2014 to 2014
$538k
NIH HHS AOD18013-001NIH HHS AOD18013-001-00000NIH HHS AOD19020-001NIH HHS AOD19020-001-00000
6 · The paper itself

Abstract

Benzodiazepines are the primary treatment option for organophosphate (OP)-induced status epilepticus (SE), but these antiseizure drugs (ASDs) lose efficacy as treatment is delayed. In the event of a mass civilian or military exposure, significant treatment delays are likely. New ASDs that combat benzodiazepine-resistant, OP-induced SE are critically needed, particularly if they can be efficacious after a long treatment delay. This study evaluated the efficacy of the K

Indexed as

Pharmaceutical PreparationsStatus EpilepticusAnimalsAnticonvulsantsCarbamatesHumansMaleOrganophosphatesPhenylenediaminesRatsRats, Sprague-DawleyTime-to-TreatmentAnticonvulsantsCarbamatesezogabineOrganophosphatesPharmaceutical PreparationsPhenylenediaminesdiisopropyl fluorophosphateelectroencephalogramfluoro-Jade Bnerve agentratsoman

Identifiers

PMID33836243
PMCPMC8142924
OpenAlexW3147277511

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.